BR112023018619A2 - Inibidores de heteroaril de calicreína plasmática - Google Patents
Inibidores de heteroaril de calicreína plasmáticaInfo
- Publication number
- BR112023018619A2 BR112023018619A2 BR112023018619A BR112023018619A BR112023018619A2 BR 112023018619 A2 BR112023018619 A2 BR 112023018619A2 BR 112023018619 A BR112023018619 A BR 112023018619A BR 112023018619 A BR112023018619 A BR 112023018619A BR 112023018619 A2 BR112023018619 A2 BR 112023018619A2
- Authority
- BR
- Brazil
- Prior art keywords
- plasma
- kalykrein
- inhibitors
- heteroaryl
- heteroaryl inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000003827 Plasma Kallikrein Human genes 0.000 abstract 2
- 108090000113 Plasma Kallikrein Proteins 0.000 abstract 2
- 229940127379 Kallikrein Inhibitors Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162468P | 2021-03-17 | 2021-03-17 | |
| PCT/US2022/020482 WO2022197758A1 (en) | 2021-03-17 | 2022-03-16 | Heteroaryl inhibitors of plasma kallikrein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023018619A2 true BR112023018619A2 (pt) | 2023-11-28 |
Family
ID=81328275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023018619A BR112023018619A2 (pt) | 2021-03-17 | 2022-03-16 | Inibidores de heteroaril de calicreína plasmática |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240228488A1 (https=) |
| EP (2) | EP4308230A1 (https=) |
| JP (1) | JP2024516073A (https=) |
| KR (1) | KR20240004296A (https=) |
| CN (1) | CN117355521A (https=) |
| AU (1) | AU2022240596A1 (https=) |
| BR (1) | BR112023018619A2 (https=) |
| CA (1) | CA3208243A1 (https=) |
| MX (1) | MX2023011014A (https=) |
| WO (1) | WO2022197758A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3765459A1 (en) | 2018-03-13 | 2021-01-20 | Shire Human Genetic Therapies, Inc. | Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof |
| EP4031245A1 (en) | 2019-09-18 | 2022-07-27 | Takeda Pharmaceutical Company Limited | Heteroaryl plasma kallikrein inhibitors |
| DK4031547T3 (da) | 2019-09-18 | 2024-09-09 | Takeda Pharmaceuticals Co | Plasmakallikreininhibitorer og anvendelser deraf |
| CN117396473A (zh) * | 2021-03-17 | 2024-01-12 | 武田药品工业株式会社 | 血浆激肽释放酶的咪唑并吡啶基抑制剂 |
| BR112023018619A2 (pt) | 2021-03-17 | 2023-11-28 | Takeda Pharmaceuticals Co | Inibidores de heteroaril de calicreína plasmática |
| EP4590663A2 (en) * | 2022-09-21 | 2025-07-30 | Takeda Pharmaceutical Company Limited | Synthesis of cyclopropane carboxylic acids |
| EP4735442A1 (en) * | 2023-06-29 | 2026-05-06 | Theranib Inc. | IMIDAZO[1,2-alpha]PYRIDINE COMPOUNDS FOR USE IN TREATING CANCER AND INFLAMMATORY DISEASES AND METHODS TO PREPARE SAID COMPOUNDS |
| CN117069662A (zh) * | 2023-10-17 | 2023-11-17 | 峰成医药科技(天津)有限公司 | 一种4,6-二氯-2-（二氟甲基）嘧啶的合成方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| GB201421088D0 (en) * | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| US9815853B2 (en) * | 2015-06-12 | 2017-11-14 | Global Blood Therapeutics, Inc. | Bridged bicyclic kallikrein inhibitors |
| EP3765459A1 (en) | 2018-03-13 | 2021-01-20 | Shire Human Genetic Therapies, Inc. | Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof |
| BR112023018619A2 (pt) | 2021-03-17 | 2023-11-28 | Takeda Pharmaceuticals Co | Inibidores de heteroaril de calicreína plasmática |
-
2022
- 2022-03-16 BR BR112023018619A patent/BR112023018619A2/pt unknown
- 2022-03-16 EP EP22716137.9A patent/EP4308230A1/en active Pending
- 2022-03-16 MX MX2023011014A patent/MX2023011014A/es unknown
- 2022-03-16 KR KR1020237034887A patent/KR20240004296A/ko active Pending
- 2022-03-16 JP JP2023557140A patent/JP2024516073A/ja active Pending
- 2022-03-16 CA CA3208243A patent/CA3208243A1/en active Pending
- 2022-03-16 WO PCT/US2022/020482 patent/WO2022197758A1/en not_active Ceased
- 2022-03-16 CN CN202280022472.XA patent/CN117355521A/zh active Pending
- 2022-03-16 EP EP25179074.7A patent/EP4585265A3/en active Pending
- 2022-03-16 US US18/550,306 patent/US20240228488A1/en active Pending
- 2022-03-16 AU AU2022240596A patent/AU2022240596A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3208243A1 (en) | 2022-09-22 |
| EP4585265A3 (en) | 2025-10-15 |
| EP4585265A2 (en) | 2025-07-16 |
| MX2023011014A (es) | 2023-12-06 |
| AU2022240596A1 (en) | 2023-10-19 |
| JP2024516073A (ja) | 2024-04-12 |
| CN117355521A (zh) | 2024-01-05 |
| WO2022197758A1 (en) | 2022-09-22 |
| US20240228488A1 (en) | 2024-07-11 |
| EP4308230A1 (en) | 2024-01-24 |
| KR20240004296A (ko) | 2024-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023018619A2 (pt) | Inibidores de heteroaril de calicreína plasmática | |
| BR112021024108A2 (pt) | Inibidores de tead e usos dos mesmos | |
| EP4477220A3 (en) | Plasma kallikrein inhibitors and uses thereof | |
| BR112021024224A2 (pt) | Inibidores de tead e usos dos mesmos | |
| MX2022007527A (es) | Inhibidores de proteinas kras mutantes. | |
| BR112018006034A2 (pt) | compostos bicíclicos como inibidores de atx | |
| CL2021003373A1 (es) | Nuevos inhibidores de egfr | |
| BR112022011651A2 (pt) | Degradadores de irak e usos dos mesmos | |
| MX2018006288A (es) | Inhibidores de acc tipo ester y usos de los mismos. | |
| ZA202005326B (en) | Heteroaryl compounds as type ii irak inhibitors and uses hereof | |
| CO2019009373A2 (es) | Compuestos heterocíclicos útiles como inhibidores duales de atx/ca. | |
| CU20220005A7 (es) | Inhibidores tricíclicos de kars dependientes de akr1c3 | |
| MX389367B (es) | Composiciones farmaceuticas liquidas que comprenden inhibidores de sglt-2. | |
| BR112018003812A2 (pt) | compostos de heteroarila como inibidores de irak e usos dos mesmos | |
| MX2022006711A (es) | Nuevos inhibidores de braf como rompedores de la paradoja. | |
| BR112015032595A8 (pt) | inibidores de ido | |
| MX2019001011A (es) | Compuestos farmaceuticos. | |
| BR112019001158A2 (pt) | formas de succinato e composições de inibidores da tirosina quinase de bruton | |
| BR112018008506B8 (pt) | Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos | |
| SA519410093B1 (ar) | مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز | |
| BR112022022608A2 (pt) | Compostos como inibidores de bcl-2 | |
| DOP2022000070A (es) | Inhibidor de diacilglicerol aciltransferasa 2 | |
| BR112022001365A2 (pt) | Formas cristalinas de um inibidor de cd73 | |
| CL2020001687A1 (es) | Nuevos compuestos inhibidores del blanco mecanístico de rapamicina (mtor). | |
| ECSP18018793A (es) | Compuestos útiles para inhibir ror-gamma-t |